Research programme: RNA-based tuberculosis therapies - Sarepta Therapeutics/Karolinska Institutet

Drug Profile

Research programme: RNA-based tuberculosis therapies - Sarepta Therapeutics/Karolinska Institutet

Alternative Names: Bacterial PPMO for TB - Sarepta Therapeutics

Latest Information Update: 16 Jul 2012

Price : $50

At a glance

  • Originator AVI BioPharma; Karolinska Institute
  • Developer Karolinska Institute; Sarepta Therapeutics
  • Class RNA
  • Mechanism of Action Gene expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Research Tuberculosis

Most Recent Events

  • 12 Jul 2012 Early research is ongoing in the US and Sweden
  • 12 Jul 2012 AVI BioPharma is now called Sarepta Therapeutics
  • 05 Jan 2011 Early research in Tuberculosis in Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top